FDA granted Priority Review for the BLA submission of the SkinTE product.
2 reports, 1 independent
Updated Sep 16
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Priority Review for the BLA submission of the SkinTE product.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Mesoblast is seeking FDA review of the BLA for its product rexlemestrocel-L.
- FDA and Pfizer are seeking regulatory approval for their products.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA reviewed protocol amendment and interim safety data for a company's product.